Literature DB >> 23150176

MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma.

Martina Redova1, Alexandr Poprach, Andrej Besse, Robert Iliev, Jana Nekvindova, Radek Lakomy, Lenka Radova, Marek Svoboda, Jan Dolezel, Rostislav Vyzula, Ondrej Slaby.   

Abstract

Renal cell carcinoma (RCC) is the most common neoplasm of adult kidney accounting for about 3 % of adult malignancies. MicroRNAs (miRNAs) are a class of naturally occurring, short non-coding RNAs that regulate gene expression at the post-transcriptional level. We determined global miRNA expression profiles of RCC and parallel renal parenchyma tissues by using quantitative reverse transcriptase-polymerase chain reaction-based TaqMan low-density arrays. Afterward, we validated the difference in miR-210 expression levels on the larger group of RCC patients (35 RCC versus 10 non-tumorous parenchyma samples). Functional in vitro experiments were performed on ACHN and CAKI-2 RCC cell lines transfected with miRNA-210 inhibitor. Cell viability, apoptosis, cell cycle, scratch wound migration assay, and invasion assay (xCELLigence) were performed. We have identified original ccRCC-specific miRNA signature in clinical samples (73 miRNAs were significantly downregulated and five miRNAs upregulated (P < 0.003)). Increased expression levels of miR-210 in RCC tumor tissue were independently validated. We observed decreased viability of ACHN and CAKI-2 cells and accumulation of CAKI-2 in G2 phase of cell cycle after silencing of miR-210 expression. Downregulation of miR-210 also reduced the migratory and invasive potential of ACHN metastatic RCC cells. Moreover, we showed downregulation of HIF1a protein in both cell lines after miR-210 silencing indicating participation of miR-210 in hypoxic processes of RCC not only through regulation of its target mRNAs but also by indirect regulation of HIF1a. To our knowledge, this is the first report to show miR-210 regulatory effects on cell migration, invasive potential, and HIF1a protein in RCC cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23150176     DOI: 10.1007/s13277-012-0573-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  29 in total

Review 1.  Bioconductor: an open source framework for bioinformatics and computational biology.

Authors:  Mark Reimers; Vincent J Carey
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

2.  MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3.

Authors:  Pasquale Fasanaro; Yuri D'Alessandra; Valeria Di Stefano; Roberta Melchionna; Sveva Romani; Giulio Pompilio; Maurizio C Capogrossi; Fabio Martelli
Journal:  J Biol Chem       Date:  2008-04-16       Impact factor: 5.157

3.  Microarray analysis of microRNA expression in renal clear cell carcinoma.

Authors:  Y Huang; Y Dai; J Yang; T Chen; Y Yin; M Tang; C Hu; L Zhang
Journal:  Eur J Surg Oncol       Date:  2009-05-13       Impact factor: 4.424

4.  Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis.

Authors:  Yongxin Chen; Raymond L Stallings
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

Review 5.  Causes and consequences of microRNA dysregulation in cancer.

Authors:  Carlo M Croce
Journal:  Nat Rev Genet       Date:  2009-10       Impact factor: 53.242

6.  Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis.

Authors:  Tsz-Fung F Chow; Youssef M Youssef; Evi Lianidou; Alexander D Romaschin; R John Honey; Robert Stewart; Kenneth T Pace; George M Yousef
Journal:  Clin Biochem       Date:  2009-07-29       Impact factor: 3.281

7.  MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia.

Authors:  R Garzon; F Pichiorri; T Palumbo; M Visentini; R Aqeilan; A Cimmino; H Wang; H Sun; S Volinia; H Alder; G A Calin; C-G Liu; M Andreeff; C M Croce
Journal:  Oncogene       Date:  2007-01-29       Impact factor: 9.867

8.  Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy.

Authors:  Ondrej Slaby; Jana Jancovicova; Radek Lakomy; Marek Svoboda; Alexandr Poprach; Pavel Fabian; Leos Kren; Jaroslav Michalek; Rostislav Vyzula
Journal:  J Exp Clin Cancer Res       Date:  2010-07-07

9.  MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.

Authors:  Aoife J Lowery; Nicola Miller; Amanda Devaney; Roisin E McNeill; Pamela A Davoren; Christophe Lemetre; Vladimir Benes; Sabine Schmidt; Jonathon Blake; Graham Ball; Michael J Kerin
Journal:  Breast Cancer Res       Date:  2009-05-11       Impact factor: 6.466

10.  miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer.

Authors:  Antonis Giannakakis; Raphael Sandaltzopoulos; Joel Greshock; Shun Liang; Jia Huang; Kosei Hasegawa; Chunsheng Li; Ann O'Brien-Jenkins; Dionyssios Katsaros; Barbara L Weber; Celeste Simon; George Coukos; Lin Zhang
Journal:  Cancer Biol Ther       Date:  2007-11-14       Impact factor: 4.742

View more
  32 in total

Review 1.  HypoxamiRs and cancer: from biology to targeted therapy.

Authors:  Harriet E Gee; Cristina Ivan; George A Calin; Mircea Ivan
Journal:  Antioxid Redox Signal       Date:  2013-11-22       Impact factor: 8.401

2.  Small Molecule Inhibition of microRNA-210 Reprograms an Oncogenic Hypoxic Circuit.

Authors:  Matthew G Costales; Christopher L Haga; Sai Pradeep Velagapudi; Jessica L Childs-Disney; Donald G Phinney; Matthew D Disney
Journal:  J Am Chem Soc       Date:  2017-02-27       Impact factor: 15.419

3.  MiR-205 functions as a tumor suppressor in adenocarcinoma and an oncogene in squamous cell carcinoma of esophagus.

Authors:  Renata Hezova; Alena Kovarikova; Josef Srovnal; Milada Zemanova; Tomas Harustiak; Jiri Ehrmann; Marian Hajduch; Milana Sachlova; Marek Svoboda; Ondrej Slaby
Journal:  Tumour Biol       Date:  2015-12-28

4.  miR-145 functions as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma.

Authors:  Ruijing Lu; Ziliang Ji; Xiaoqing Li; Qingna Zhai; Chunjuan Zhao; Zhimao Jiang; Shiqiang Zhang; Liping Nie; Zhendong Yu
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-03       Impact factor: 4.553

Review 5.  The regulation and function of microRNAs in kidney diseases.

Authors:  Qingqing Wei; Qing-Sheng Mi; Zheng Dong
Journal:  IUBMB Life       Date:  2013-07       Impact factor: 3.885

6.  MiR-210 expression reverses radioresistance of stem-like cells of oesophageal squamous cell carcinoma.

Authors:  Xin Chen; Jia Guo; Ru-Xing Xi; Yu-Wei Chang; Fei-Yang Pan; Xiao-Zhi Zhang
Journal:  World J Clin Oncol       Date:  2014-12-10

7.  Effects of a 28-day dietary co-exposure to melamine and cyanuric acid on the levels of serum microRNAs in male and female Fisher 344 rats.

Authors:  Camila S Silva; Ching-Wei Chang; Denita Williams; Patricia Porter-Gill; Gonçalo Gamboa da Costa; Luísa Camacho
Journal:  Food Chem Toxicol       Date:  2016-09-09       Impact factor: 6.023

8.  miR-372 suppresses tumour proliferation and invasion by targeting IGF2BP1 in renal cell carcinoma.

Authors:  Xuan Huang; Mingjie Huang; Lingbao Kong; Yong Li
Journal:  Cell Prolif       Date:  2015-10       Impact factor: 6.831

9.  Global and Targeted miRNA Expression Profiling in Clear Cell Renal Cell Carcinoma Tissues Potentially Links miR-155-5p and miR-210-3p to both Tumorigenesis and Recurrence.

Authors:  Jinhua Zhang; Yuanqing Ye; David W Chang; Shu-Hong Lin; Maosheng Huang; Nizar M Tannir; Surena Matin; Jose A Karam; Christopher G Wood; Zhi-Nan Chen; Xifeng Wu
Journal:  Am J Pathol       Date:  2018-09-08       Impact factor: 4.307

Review 10.  miR-210: fine-tuning the hypoxic response.

Authors:  Mircea Ivan; Xin Huang
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.